Five Prime Therapeutics Inc (FPRX) - Financial and Strategic SWOT Analysis Review

Five Prime Therapeutics Inc (FPRX) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH136045FSA
  • |
  • Pages: 52
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Five Prime Therapeutics Inc (FPRX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Five Prime Therapeutics Inc (Five Prime) is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company's developmental pipeline is based on the discovery platform and library of therapeutic proteins. The company's pipeline products include cabiralizumab,; FPA144; FPT-155; FPA-150; FPA-151; Tim- 3 antibody; novel I-O biologics and I-O antibody for treating various forms of cancer. Five Prime has also developed proprietary protein screening technologies and rapid in vivo protein production system to identify new targets for protein therapeutics. The company has development collaborations with companies such as Bristol-Myers Squibb, GlaxoSmithKline, Zai Lab, Galaxy Biotech, BioWa-Lonza and UCB Pharma. Five Prime is headquartered in South San Francisco, California, the US.

Five Prime Therapeutics Inc Key Recent Developments

May 29,2018: Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018

May 15,2018: Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer

May 08,2018: Five Prime Therapeutics Reports First Quarter 2018 Financial Results

Mar 13,2018: Five Prime Therapeutics Announces Executive Change

Feb 27,2018: Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Five Prime Therapeutics Inc-Key Facts 6

Five Prime Therapeutics Inc-Key Employees 7

Five Prime Therapeutics Inc-Key Employee Biographies 8

Five Prime Therapeutics Inc-Major Products and Services 9

Five Prime Therapeutics Inc-History 10

Five Prime Therapeutics Inc-Company Statement 12

Five Prime Therapeutics Inc-Locations And Subsidiaries 13

Head Office 13

Section 2-Company Analysis 14

Company Overview 14

Five Prime Therapeutics Inc-Business Description 15

Five Prime Therapeutics Inc-Corporate Strategy 16

Five Prime Therapeutics Inc-SWOT Analysis 17

SWOT Analysis-Overview 17

Five Prime Therapeutics Inc-Strengths 17

Five Prime Therapeutics Inc-Weaknesses 18

Five Prime Therapeutics Inc-Opportunities 19

Five Prime Therapeutics Inc-Threats 20

Five Prime Therapeutics Inc-Key Competitors 21

Section 3-Company Financial Ratios 22

Financial Ratios-Capital Market Ratios 22

Financial Ratios-Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios-Interim Ratios 26

Financial Ratios-Ratio Charts 27

Section 4-Company's Lifesciences Financial Deals and Alliances 28

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Five Prime Therapeutics Inc, Recent Deals Summary 30

Section 5-Company's Recent Developments 31

May 29, 2018: Five Prime Therapeutics Walks to End Pancreatic Cancer at PurpleStride San Francisco 2018 31

May 15, 2018: Five Prime Therapeutics Appoints Bryan Irving, Ph.D., as Chief Scientific Officer 32

Mar 13, 2018: Five Prime Therapeutics Announces Executive Change 33

Feb 27, 2018: Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results 34

Nov 06, 2017: Five Prime Announces Third Quarter 2017 Results and Provides Business Update 38

Oct 23, 2017: Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018 40

Aug 17, 2017: Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research 41

Aug 08, 2017: Five Prime Announces Second Quarter 2017 Results and Provides Business Update 42

Jun 21, 2017: Five Prime Therapeutics Announces Lewis T. Rusty Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018 46

May 15, 2017: Five Prime Welcomes Garry Nicholson to Board of Directors 47

Section 6-Appendix 48

Methodology 48

Ratio Definitions 48

About GlobalData 52

Contact Us 52

Disclaimer 52

List of Figures

Five Prime Therapeutics Inc, Performance Chart (2013-2017) 25

Five Prime Therapeutics Inc, Ratio Charts 27

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

List of Tables

Five Prime Therapeutics Inc, Key Facts 6

Five Prime Therapeutics Inc, Key Employees 7

Five Prime Therapeutics Inc, Key Employee Biographies 8

Five Prime Therapeutics Inc, Major Products and Services 9

Five Prime Therapeutics Inc, History 10

Five Prime Therapeutics Inc, Key Competitors 21

Five Prime Therapeutics Inc, Ratios based on current share price 22

Five Prime Therapeutics Inc, Annual Ratios 23

Five Prime Therapeutics Inc, Annual Ratios (Cont...1) 24

Five Prime Therapeutics Inc, Interim Ratios 26

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Five Prime Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Five Prime Therapeutics Inc, Recent Deals Summary 30

Currency Codes 48

Capital Market Ratios 48

Equity Ratios 49

Profitability Ratios 49

Cost Ratios 50

Liquidity Ratios 50

Leverage Ratios 51

Efficiency Ratios 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Rexahn Pharmaceuticals Inc

Onconova Therapeutics, Inc. (New Jersey Office)

Moleculin Biotech LLC

Fortress Biotech Inc

CytRx Corp

Five Prime Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8905
Site License
USD 250 INR 17810
Corporate User License
USD 375 INR 26715

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com